Bispecific antibodies are one of the hottest areas for drug research and dealmaking, and several of them were discussed this week during the annual J.P. Morgan Healthcare Conference in San Francisco. Takeda President, Research and Development, Andy Plump talked to MedCity News about what sets the Japanese pharma company’s newly licensed drug apart.
The post Takeda R&D Exec Explains How $1.2B Deal Could Become One of the Biggest Bargains in Drug History appeared first on MedCity News.
